1. Home
  2. RIGL vs HIFS Comparison

RIGL vs HIFS Comparison

Compare RIGL & HIFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
    SELLHOLDBUYas of 13 hours ago
  • HIFS
    SELLHOLDBUYas of 13 hours ago
  • Stock Information
  • Founded
  • RIGL 1996
  • HIFS 1834
  • Country
  • RIGL United States
  • HIFS United States
  • Employees
  • RIGL N/A
  • HIFS N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • HIFS Major Banks
  • Sector
  • RIGL Health Care
  • HIFS Finance
  • Exchange
  • RIGL Nasdaq
  • HIFS Nasdaq
  • Market Cap
  • RIGL 486.4M
  • HIFS 541.8M
  • IPO Year
  • RIGL 2000
  • HIFS N/A
  • Fundamental
  • Price
  • RIGL $17.32
  • HIFS $248.75
  • Analyst Decision
  • RIGL Buy
  • HIFS
  • Analyst Count
  • RIGL 5
  • HIFS 0
  • Target Price
  • RIGL $34.80
  • HIFS N/A
  • AVG Volume (30 Days)
  • RIGL 316.4K
  • HIFS 8.9K
  • Earning Date
  • RIGL 11-07-2024
  • HIFS 01-17-2025
  • Dividend Yield
  • RIGL N/A
  • HIFS 0.99%
  • EPS Growth
  • RIGL N/A
  • HIFS N/A
  • EPS
  • RIGL 0.22
  • HIFS 10.55
  • Revenue
  • RIGL $157,374,000.00
  • HIFS $58,408,000.00
  • Revenue This Year
  • RIGL $48.98
  • HIFS N/A
  • Revenue Next Year
  • RIGL $14.43
  • HIFS N/A
  • P/E Ratio
  • RIGL $78.31
  • HIFS $24.09
  • Revenue Growth
  • RIGL 21.65
  • HIFS N/A
  • 52 Week Low
  • RIGL $7.48
  • HIFS $150.11
  • 52 Week High
  • RIGL $29.82
  • HIFS $300.00
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 38.25
  • HIFS 37.83
  • Support Level
  • RIGL $15.61
  • HIFS $250.36
  • Resistance Level
  • RIGL $17.36
  • HIFS $257.66
  • Average True Range (ATR)
  • RIGL 1.31
  • HIFS 6.41
  • MACD
  • RIGL -0.25
  • HIFS -1.77
  • Stochastic Oscillator
  • RIGL 50.75
  • HIFS 5.40

Stock Price Comparison Chart: RIGL vs HIFS

RIGL
HIFS
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025050100150200250300350400450RIGL VS HIFS

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About HIFS Hingham Institution for Savings

Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use